Novartis AG (VIE:NOVN)
Austria · Delayed Price · Currency is EUR | Market Cap | 255.92B +20.5% |
| Revenue (ttm) | 48.27B +9.6% |
| Net Income | 11.91B +17.1% |
| EPS | 6.09 +21.8% |
| Shares Out | n/a |
| PE Ratio | 21.49 |
| Forward PE | 17.35 |
| Dividend | 4.10 (3.03%) |
| Ex-Dividend Date | Mar 10, 2026 |
| Volume | n/a |
| Average Volume | 2 |
| Open | 133.52 |
| Previous Close | 134.86 |
| Day's Range | 133.52 - 133.52 |
| 52-Week Range | 94.21 - 143.52 |
| Beta | n/a |
| RSI | 48.09 |
| Earnings Date | Apr 28, 2026 |
About Novartis AG
Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6); Promacta/Revolade to treat immune thrombocy... [Read more]
Financial Performance
In 2025, Novartis AG's revenue was $56.67 billion, an increase of 9.57% compared to the previous year's $51.72 billion. Earnings were $13.98 billion, an increase of 17.11%.
Financial numbers in USD Financial StatementsNews
JNVST Class 6 Selection Test 2026: Admit Card Out, Download Link Here
JNVST Class 6 Admit Card 2026: Navodaya Vidyalaya Samiti (NVS) has released the Class 6 JNVST admit card for winter-bound schools. Parents and teachers can download the admit card through the direct l...
AVDE, SHEL, HSBC, NVS: ETF Inflow Alert
Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Avantis International Equity ETF (Symbol: AVDE) where we have detected...
Novartis Advances Dermatology Portfolio With Cosentyx FDA Approval For Pediatric Patients
FDA approves Novartis' Cosentyx for moderate to severe hidradenitis suppurativa in patients aged 12 and older, expanding treatment options. ... Full story available on Benzinga.com
Novartis (NVS) Announces New Share Buyback Program
Novartis (NVS) Announces New Share Buyback Program
Novartis Gains FDA Approval For Cosentyx In Pediatric Hidradenitis Suppurativa
(RTTNews) - Novartis AG (NVS) announced that the U.S. FDA has approved Cosentyx for pediatric patients aged 12 and older with moderate to severe hidradenitis suppurativa. The decision makes Cosentyx t...
Novartis (NVS) Gains FDA Approval for Pediatric Hidradenitis Suppurativa Treatment
Novartis (NVS) Gains FDA Approval for Pediatric Hidradenitis Suppurativa Treatment
Novartis Cosentyx® receives FDA approval for pediatric patients aged 12+ with moderate to severe hidradenitis suppurativa
Basel, March 13, 2026 – Novartis announced today that Cosentyx® (secukinumab) received US Food and Drug Administration (FDA) approval for treating pediatric patients 12 years and older with moderate t...
Novartis AG (NVS) Stock Price Down 3.66% on Mar 11
Novartis AG (NVS) Stock Price Down 3.66% on Mar 11
Market Outlook: Costco, Novartis and Devon among stock picks
Three stock ideas from a quantitative investing model including Costco, Novartis and Devon Energy as markets remain volatile.
Voyager Reports Fourth Quarter and Full Year 2025 Financial and Operating Results
- Transformative year for tau in AD: VY1706 clinical entry and VY7523 clinical data anticipated H2 2026 - - Validating brain-targeted capsids in humans: expect two I.V.-delivered neuro gene therapies ...
Novartis AG (NVS) Shareholder/Analyst Call Prepared Remarks Transcript
Novartis AG (NVS) Shareholder/Analyst Call Prepared Remarks Transcript
Novartis (NVS) Shareholders Approve Key Resolutions at Annual Meeting
Novartis (NVS) Shareholders Approve Key Resolutions at Annual Meeting
Novartis shareholders approve all resolutions proposed by the Board of Directors at the 2026 Annual General Meeting
Basel, March 6, 2026 – Novartis shareholders today agreed to the Board of Directors' recommendations for all proposed resolutions at the company's Annual General Meeting (AGM). A total of 1 554 shareh...
Novartis AG (NVS) Shares Down 3.08% on Mar 5
Novartis AG (NVS) Shares Down 3.08% on Mar 5
Novartis And Henrietta Lacks' Family Reach A Settlement
In this week's edition of InnovationRx, we look at the settlement between Novartis and the family of Henrietta Lacks, the startup that wants to treat Alzheimer's with microrobots, medical groups push ...
Novartis AG (NVS) Stock Price Down 3.43% on Mar 3
Novartis AG (NVS) Stock Price Down 3.43% on Mar 3
Forget Amarin: This Oft-Overlooked Pharma Powerhouse Is a Better Buy Now
Amarin's results depend on a single medicine that is already facing generic competition. By contrast, Novartis has a deep lineup, plenty of growth products, and a solid dividend program.
Commit fully to the role you’re in now, and your career may thank you later: Novartis CEO Vas Narasimhan
Guided by immigrant roots, public‑health purpose and a belief in “staying in the ring,” Novartis CEO Vas Narasimhan reflects on the unlikely decisions that took him from the “steel town” of Pittsburgh...
What's Driving the Market Sentiment Around Novartis AG?
Novartis AG's (NYSE: NVS) short interest as a percent of float has risen 44.44% since its last report. According to exchange reported data, there are now 7.49 million shares sold short , which is 0.3...
Second HeLa Lawsuit Resolved As Novartis Reaches Confidential Settlement
Novartis reached a confidential settlement with Henrietta Lacks' family, resolving a second lawsuit over the nonconsensual use of HeLa cells. ... Full story available on Benzinga.com
Henrietta Lacks: Family of woman whose cells were 'stolen' settles second lawsuit
Novartis is the second drug company to settle a lawsuit brought by the family of a woman whose cells have enabled huge advances in science.
Novartis (NVS) Expands with New Facilities and Job Creation
Novartis (NVS) Expands with New Facilities and Job Creation
The immortal life of Henrietta Lacks lawsuits gets a bit shorter with Novartis settlement
Details of the agreement, which was finalized in federal court in Maryland this month, aren't public.
Novartis (NVS) Backs Atrium Therapeutics' Launch with $270M Funding
Novartis (NVS) Backs Atrium Therapeutics' Launch with $270M Funding
Novartis (NVS) Completes Acquisition of Avidity Biosciences
Novartis (NVS) Completes Acquisition of Avidity Biosciences